Abstract
Introduction: This study evaluated the diagnostic accuracy of the Cogstate Brief Battery (CBB) for mild cognitive impairment (MCI) and prodromal Alzheimer's disease (AD) in a population-based sample. Methods: Participants included adults ages 50+ classified as cognitively unimpaired (CU, n = 2866) or MCI (n = 226), and a subset with amyloid (A) and tau (T) positron emission tomography who were AD biomarker negative (A–T–) or had prodromal AD (A+T+). Results: Diagnostic accuracy of the Learning/Working Memory Composite (Lrn/WM) for discriminating all CU and MCI was moderate (area under the curve [AUC] = 0.75), but improved when discriminating CU A–T– and MCI A+T+ (AUC = 0.93) and when differentiating MCI participants without AD biomarkers from those with prodromal AD (AUC = 0.86). Conventional cut-offs yielded lower than expected sensitivity for both MCI (38%) and prodromal AD (73%). Discussion: Clinical utility of the CBB for detecting MCI in a population-based sample is lower than expected. Caution is needed when using currently available CBB normative data for clinical interpretation.
Original language | English (US) |
---|---|
Pages (from-to) | 584-594 |
Number of pages | 11 |
Journal | Alzheimer's and Dementia |
Volume | 17 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2021 |
Keywords
- Alzheimer's disease
- amyloid
- cognigram
- memory
- mild cognitive impairment
- neuropsychology
- one back
- one card learning
- sensitivity and specificity
- tau
ASJC Scopus subject areas
- Epidemiology
- Health Policy
- Developmental Neuroscience
- Clinical Neurology
- Geriatrics and Gerontology
- Cellular and Molecular Neuroscience
- Psychiatry and Mental health